AAPL332.56+5.99 (+1.83%) ▲|ABBV257.01+2.01 (+0.79%) ▲|ABT102.12-1.24 (-1.20%) ▼|ACN183.71+5.80 (+3.26%) ▲|ADBE253.64+4.81 (+1.93%) ▲|AMAT457.52+3.51 (+0.77%) ▲|AMD516.23+12.63 (+2.51%) ▲|AMGN378.14-4.33 (-1.13%) ▼|AMT178.05+5.07 (+2.93%) ▲|AMZN257.23+5.34 (+2.12%) ▲|AVGO362.85+2.02 (+0.56%) ▲|AXP324.25+3.54 (+1.10%) ▲|BA210.62+5.82 (+2.84%) ▲|BAC62.73+0.17 (+0.26%) ▲|BKNG174.01+0.10 (+0.06%) ▲|BLK1,081.85+19.45 (+1.83%) ▲|BMY63.47-0.28 (-0.44%) ▼|BNY162.85+0.26 (+0.16%) ▲|BRK-B509.53+2.53 (+0.50%) ▲|C138.96+0.46 (+0.33%) ▲|CAT819.79+14.79 (+1.84%) ▲|CL86.45-1.45 (-1.65%) ▼|CMCSA25.16-0.01 (-0.04%) ▼|COF208.31+1.20 (+0.58%) ▲|COP136.75-0.30 (-0.22%) ▼|COST905.17+2.79 (+0.31%) ▲|CRM248.34+5.34 (+2.20%) ▲|CSCO111.64+4.20 (+3.91%) ▲|CVS94.47-0.82 (-0.86%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE676.98-0.96 (-0.14%) ▼|DHR200.43-0.11 (-0.05%) ▼|DIS106.50+0.68 (+0.64%) ▲|DUK119.41+0.04 (+0.03%) ▲|EMR152.04+3.67 (+2.47%) ▲|FDX312.41+0.61 (+0.20%) ▲|GD356.43+2.18 (+0.62%) ▲|GE324.16+0.01 (+0.00%) ▲|GEV956.03+32.12 (+3.48%) ▲|GILD143.94-0.87 (-0.60%) ▼|GM85.70-0.42 (-0.49%) ▼|GOOG336.04+5.65 (+1.71%) ▲|GOOGL339.05+6.45 (+1.94%) ▲|GS1,028.66+8.89 (+0.87%) ▲|HD309.02+3.33 (+1.09%) ▲|HON201.95-0.23 (-0.11%) ▼|IBM242.75+8.73 (+3.73%) ▲|INTC103.05+2.73 (+2.72%) ▲|INTU322.30+9.53 (+3.05%) ▲|ISRG371.30+10.84 (+3.01%) ▲|JNJ265.82-0.54 (-0.20%) ▼|JPM356.26+2.70 (+0.76%) ▲|KO88.47+0.64 (+0.73%) ▲|LIN466.99+5.37 (+1.16%) ▲|LLY1,118.14-4.86 (-0.43%) ▼|LMT524.52-5.60 (-1.06%) ▼|LOW196.94+0.35 (+0.18%) ▲|LRCX299.05+1.04 (+0.35%) ▲|MA572.42+7.05 (+1.25%) ▲|MCD252.83-0.22 (-0.09%) ▼|MDLZ62.38-0.09 (-0.14%) ▼|MDT90.78-0.84 (-0.91%) ▼|META649.36+4.98 (+0.77%) ▲|MMM164.85+1.99 (+1.22%) ▲|MO69.00+0.21 (+0.30%) ▲|MRK144.46-0.26 (-0.18%) ▼|MS214.50+1.84 (+0.87%) ▲|MSFT496.93+4.49 (+0.91%) ▲|MU975.69-1.72 (-0.18%) ▼|NEE82.39-0.06 (-0.07%) ▼|NFLX77.51+1.50 (+1.97%) ▲|NKE36.89+0.27 (+0.72%) ▲|NOW132.81+1.64 (+1.25%) ▲|NVDA218.51+0.15 (+0.07%) ▲|ORCL151.13-1.81 (-1.18%) ▼|PEP136.28-0.37 (-0.27%) ▼|PFE27.62-0.03 (-0.12%) ▼|PG145.07+2.10 (+1.47%) ▲|PLTR167.54+1.68 (+1.02%) ▲|PM192.92+3.15 (+1.66%) ▲|QCOM182.35+5.47 (+3.09%) ▲|RTX197.48-0.64 (-0.32%) ▼|SBUX98.82-0.41 (-0.41%) ▼|SCHW107.02-0.31 (-0.29%) ▼|SO87.20-0.55 (-0.63%) ▼|SPG205.02+0.35 (+0.17%) ▲|T26.05+0.50 (+1.96%) ▲|TMO613.07+9.89 (+1.64%) ▲|TMUS183.34+6.18 (+3.49%) ▲|TSLA365.06+1.50 (+0.41%) ▲|TXN268.45+9.63 (+3.72%) ▲|UBER71.80-0.76 (-1.05%) ▼|UNH378.39-9.89 (-2.55%) ▼|UNP284.76-1.02 (-0.36%) ▼|UPS99.95-0.03 (-0.03%) ▼|USB62.84+0.43 (+0.68%) ▲|V371.10+3.89 (+1.06%) ▲|VZ50.52+0.55 (+1.09%) ▲|WFC90.12+0.67 (+0.74%) ▲|WMT107.14+1.41 (+1.33%) ▲|XOM165.30+0.07 (+0.04%) ▲|AAPL332.56+5.99 (+1.83%) ▲|ABBV257.01+2.01 (+0.79%) ▲|ABT102.12-1.24 (-1.20%) ▼|ACN183.71+5.80 (+3.26%) ▲|ADBE253.64+4.81 (+1.93%) ▲|AMAT457.52+3.51 (+0.77%) ▲|AMD516.23+12.63 (+2.51%) ▲|AMGN378.14-4.33 (-1.13%) ▼|AMT178.05+5.07 (+2.93%) ▲|AMZN257.23+5.34 (+2.12%) ▲|AVGO362.85+2.02 (+0.56%) ▲|AXP324.25+3.54 (+1.10%) ▲|BA210.62+5.82 (+2.84%) ▲|BAC62.73+0.17 (+0.26%) ▲|BKNG174.01+0.10 (+0.06%) ▲|BLK1,081.85+19.45 (+1.83%) ▲|BMY63.47-0.28 (-0.44%) ▼|BNY162.85+0.26 (+0.16%) ▲|BRK-B509.53+2.53 (+0.50%) ▲|C138.96+0.46 (+0.33%) ▲|CAT819.79+14.79 (+1.84%) ▲|CL86.45-1.45 (-1.65%) ▼|CMCSA25.16-0.01 (-0.04%) ▼|COF208.31+1.20 (+0.58%) ▲|COP136.75-0.30 (-0.22%) ▼|COST905.17+2.79 (+0.31%) ▲|CRM248.34+5.34 (+2.20%) ▲|CSCO111.64+4.20 (+3.91%) ▲|CVS94.47-0.82 (-0.86%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE676.98-0.96 (-0.14%) ▼|DHR200.43-0.11 (-0.05%) ▼|DIS106.50+0.68 (+0.64%) ▲|DUK119.41+0.04 (+0.03%) ▲|EMR152.04+3.67 (+2.47%) ▲|FDX312.41+0.61 (+0.20%) ▲|GD356.43+2.18 (+0.62%) ▲|GE324.16+0.01 (+0.00%) ▲|GEV956.03+32.12 (+3.48%) ▲|GILD143.94-0.87 (-0.60%) ▼|GM85.70-0.42 (-0.49%) ▼|GOOG336.04+5.65 (+1.71%) ▲|GOOGL339.05+6.45 (+1.94%) ▲|GS1,028.66+8.89 (+0.87%) ▲|HD309.02+3.33 (+1.09%) ▲|HON201.95-0.23 (-0.11%) ▼|IBM242.75+8.73 (+3.73%) ▲|INTC103.05+2.73 (+2.72%) ▲|INTU322.30+9.53 (+3.05%) ▲|ISRG371.30+10.84 (+3.01%) ▲|JNJ265.82-0.54 (-0.20%) ▼|JPM356.26+2.70 (+0.76%) ▲|KO88.47+0.64 (+0.73%) ▲|LIN466.99+5.37 (+1.16%) ▲|LLY1,118.14-4.86 (-0.43%) ▼|LMT524.52-5.60 (-1.06%) ▼|LOW196.94+0.35 (+0.18%) ▲|LRCX299.05+1.04 (+0.35%) ▲|MA572.42+7.05 (+1.25%) ▲|MCD252.83-0.22 (-0.09%) ▼|MDLZ62.38-0.09 (-0.14%) ▼|MDT90.78-0.84 (-0.91%) ▼|META649.36+4.98 (+0.77%) ▲|MMM164.85+1.99 (+1.22%) ▲|MO69.00+0.21 (+0.30%) ▲|MRK144.46-0.26 (-0.18%) ▼|MS214.50+1.84 (+0.87%) ▲|MSFT496.93+4.49 (+0.91%) ▲|MU975.69-1.72 (-0.18%) ▼|NEE82.39-0.06 (-0.07%) ▼|NFLX77.51+1.50 (+1.97%) ▲|NKE36.89+0.27 (+0.72%) ▲|NOW132.81+1.64 (+1.25%) ▲|NVDA218.51+0.15 (+0.07%) ▲|ORCL151.13-1.81 (-1.18%) ▼|PEP136.28-0.37 (-0.27%) ▼|PFE27.62-0.03 (-0.12%) ▼|PG145.07+2.10 (+1.47%) ▲|PLTR167.54+1.68 (+1.02%) ▲|PM192.92+3.15 (+1.66%) ▲|QCOM182.35+5.47 (+3.09%) ▲|RTX197.48-0.64 (-0.32%) ▼|SBUX98.82-0.41 (-0.41%) ▼|SCHW107.02-0.31 (-0.29%) ▼|SO87.20-0.55 (-0.63%) ▼|SPG205.02+0.35 (+0.17%) ▲|T26.05+0.50 (+1.96%) ▲|TMO613.07+9.89 (+1.64%) ▲|TMUS183.34+6.18 (+3.49%) ▲|TSLA365.06+1.50 (+0.41%) ▲|TXN268.45+9.63 (+3.72%) ▲|UBER71.80-0.76 (-1.05%) ▼|UNH378.39-9.89 (-2.55%) ▼|UNP284.76-1.02 (-0.36%) ▼|UPS99.95-0.03 (-0.03%) ▼|USB62.84+0.43 (+0.68%) ▲|V371.10+3.89 (+1.06%) ▲|VZ50.52+0.55 (+1.09%) ▲|WFC90.12+0.67 (+0.74%) ▲|WMT107.14+1.41 (+1.33%) ▲|XOM165.30+0.07 (+0.04%) ▲|
26.7 C
New York
Friday, September 11, 2026

Tag: stage

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its second-quarter 2025 financial results on Wednesday, Aug. 5, 2025, prior to the open of the U.S. financial markets.

First Citizens BancShares Reports Second Quarter 2025 Earnings, Announces Additional Share Repurchase Plan

RALEIGH, N.C., July 25, 2025 /PRNewswire/ -- First Citizens BancShares, Inc. ("BancShares") (Nasdaq: FCNCA) reported earnings for the second quarter of 2025.  ...

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

SUZHOU, China, July 25, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the...

Bitcoin Swift Presale Enters Final 24 Hours of Stage 1 with Token Fixed at $1

Stage 2 Will Introduce Price Increase and APY Adjustment as Project Prepares for Solana Deployment and AI-Driven Governance Rollout

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection

Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).

Yali Capital Raises ₹893 Crores to Back India’s Deep Tech Revolution

BENGALURU, India, July 25, 2025 /PRNewswire/ -- Yali Capital, a SEBI-registered Category II Alternative Investment Fund (AIF), today announced the successful closure of its...

Troller Cat Enters Stage 14 of Presale with $400K Raised, Announces Ethereum-Based Staking Program

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Troller Cat, a meme-inspired cryptocurrency project built on Ethereum, has officially entered Stage 14 of its 26-stage presale. With over $400,000 raised and more than 1,500 holders onboard, the project continues to gain traction amid rising demand for community-driven blockchain tokens.

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the...

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

NANJING, China, July 24, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the...

Orla Mining Provides Initial Update on Pit Wall Event at Camino Rojo

VANCOUVER, BC, July 24, 2025 /CNW/ - Orla Mining Ltd. (TSX: OLA) (NYSE: ORLA) ("Orla" or the "Company") is providing an update on the...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStage